Navigation Links
Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
Date:6/12/2008

SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced the receipt of $6.3 million of cash payments and equity investments from AnGes MG, Inc., under a previously announced collaborative agreement for continued funding of the company's ongoing Allovectin-7(R) Phase 3 metastatic melanoma trial. Through a series of cash payments and equity investments, Vical has received $15.3 million to date of the $22.6 million total committed by AnGes.

Vical is conducting the Allovectin-7(R) Immunotherapeutic for Metastatic Melanoma, or AIMM trial, a Phase 3 pivotal trial of the company's Allovectin-7(R) cancer immunotherapeutic as first-line therapy in chemotherapy-naive patients with Stage III or IV metastatic melanoma in accordance with a Special Protocol Assessment (SPA) agreement completed with the U.S. Food and Drug Administration (FDA). The SPA specifies the trial objectives and design, clinical endpoints, and planned analyses expected to be needed for product approval.

The AIMM trial calls for enrollment of approximately 375 patients with Stage III or IV metastatic melanoma, and is currently enrolling patients at clinical sites in the United States, Canada and Europe. A patient self-screening tool for trial eligibility is available online at http://www.melanomaclinicaltrial.com.

In exchange for funding the trial, AnGes received exclusive marketing rights in Japan and other key Asian countries, and also will receive certain royalties for sales in the United States and European countries. AnGes is obligated to pay Vical royalties on product sales in the specified Asian countries, plus certain sales-based milestone payments i
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
2. Promise of Vicals CMV Vaccine Noted by Independent Experts
3. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
4. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
5. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
6. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
7. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
8. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
9. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
10. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015  Becton, Dickinson and Company (NYSE: ... commence offers to exchange all validly tendered and accepted ... a wholly owned subsidiary of BD, for notes to ... below. A Registration Statement on Form S-4 (the "Registration ... was filed with the Securities and Exchange Commission ("SEC") ...
(Date:3/26/2015)... , 26. März 2015  Die ... wird vom 1. April 2015 an Zulassungsanträge für ... abgebenden Apotheken annehmen. Seit dem Start des ... Verband über 275 .pharmacy-Domainnamen zugelassen, die für ... Zeiten beantragt wurden. Die NABP startete .pharmacy ...
(Date:3/26/2015)... -- Gelesis , a clinical stage biotechnology ... to induce weight loss and improve glycemic control, ... of shares of convertible preferred stock for gross ... of approximately $4 million of outstanding convertible promissory ... to support the continued clinical development of its ...
Breaking Medicine Technology:Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5Alle abgebenden Apotheken berechtigt, um ab dem 1. April 2015 .Pharmacy-Domainnamen zu beantragen 2Gelesis Closes $22M Equity Financing 2Gelesis Closes $22M Equity Financing 3
(Date:3/26/2015)... FL (PRWEB) March 26, 2015 ... the nation’s leading innovative specialty pharmacies, announces the ... position of Vice President of Pharmaceutical Relations. In ... beneficial connections with our pharmaceuticals partners and providing ... in support of BioPlus’ expansion. , “Over ...
(Date:3/26/2015)... In the key developed markets, the hypertension ... is set to decrease through 2020 at a negative CAGR ... expected up to 2017 at a 2.6% CAGR and a ... to the surging penetration of fixed-dose combination drugs like Azor, ... Benicar HCT, and Tekamlo), a hike in the prevalence population ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Leading ... brand-new, state-of-the-art company website: http://www.metabolicnutrition.com . ... revamped website creates a user-friendly experience for consumers ... , The new, enhanced Metabolic Nutrition website ... about the company’s diverse line of products, conveniently ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Zane Benefits, ... businesses, announced a new eBook, “The Comprehensive Guide To ... eBook, interviewing is the most important aspect of the ... they are hiring the right way, possibly resulting in ... be an arduous undertaking, yet it’s essential to the ...
(Date:3/26/2015)... 26, 2015 LinkToBanking, a Preferred ... names Tom Fleming as Chairman of the Board ... effective immediately. With their combined knowledge and ... industry, Mr. Fleming and Mr. Casares will provide ... to cannabis related businesses. , About Tom Fleming, ...
Breaking Medicine News(10 mins):Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:Metabolic Nutrition Launches Sleek New Website with New Features and Enhanced Consumer Information 2Health News:Zane Benefits Announces: New eBook: The Comprehensive Guide To Interviewing For Your Small Business 2Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 2Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 3
... toll was so overwhelming that steam shovels were brought in ... trains commandeered to transport dead soldiers and priests could be ... threat of another flu pandemic looming in the not too ... preparations for it mortuary specialists are once more faced with ...
... babies much before the full term are administered steroids. ... the University of Adelaide , has found that subjecting ... babies by reducing potential breathing difficulties during delivery. ... babies from the Adelaide Women's and Children's Hospital. Research ...
... to introduce a system in which the GPs would be graded ... government to vote in favor for the new scheme of grading ... According to this the surgeries were to be inspected by doctors, ... one to three. It was a modification of the accreditation scheme. ...
... which is already running in a loss would have to pay ... are not in a position // to fulfil the commitment to ... health services. ,The trusts in the south of England ... ?20bn scheme under a deal with Japanese firm Fujitsu. But the ...
... Cheltenham Science Festival that it plans to send a ... //a research into the effects of low oxygen levels, ... for Aviation, Space and Extreme Environment Medicine at the ... will be conducting the research along with researchers around ...
... In a breakthrough move against HIV drug resistance, scientists have now ... that is the first in a new class of HIV drug ... Caspsid, a key viral protein from its precursor protein,this group of ... acid, and interferes with the production of the capsid conical ...
Cached Medicine News:Health News:What to do with the Dead if a Flu Outbreak Happens? 2Health News:Already Short Staffed And In Deficit NHS Fails To Supply Staff For IT Project 2Health News:Mount Everest to be Site of Research into Hypoxia 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: